London, UK: 12 July, 2006 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces that three Non-Executive Directors of Antisoma have taken part of their fees for the quarter ended 30 June 2006 in shares pursuant to resolutions of the Board of Directors dated 14 September 2004 and subsequently.

The newly issued shares were issued at a price of 16.25p per share, being the mid-market closing price on the last trading day of the quarter (30 June 2006). The relevant Directors have agreed not to dispose of the shares allotted to them for a minimum period of one year.

The allotment and total holdings following these allotments are shown below.

Director Allotted Total Percentage of 12 July 06 holding issued ordinary shares

Grahame Cook 22,307 470,044 0.13% Michael 17,307 576,571 0.16% Pappas Dale Boden 17,884 587,362* 0.16%

* Mr Boden's total holdings include a beneficial interest totalling 538,469 ordinary Antisoma shares held by BF Capital, BFC III Ltd and by The Sentinel I Trust.

Application will be made to the London Stock Exchange and the UK Listing Authority for the admission of the 57,498 new ordinary shares of 1p each. The total number of ordinary shares in the Company in issue and admitted to the Official List following the above allotments will be 370,846,378.

The shares when issued will rank pari passu with the company's existing ordinary shares.

Enquiries: Raymond Spencer, CFO +44 (0)208 799 8200 Daniel Elger, Director of Communications Antisoma plc

Mark Court/Lisa Baderoon/Rebecca Skye Dietrich +44 (0)20 7466 5000 Buchanan Communications

Background on Antisoma Based in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Please visit www.antisoma.co.uk for further information about Antisoma.

---END OF MESSAGE---